Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Is AbbVie (ABBV) Poised to Beat Earnings Estimates?
Yahoo/Zacks.com
Thursday, January 30, 2014 - 2:51pm
tags:
earnings, AbbVie
Eyes Down For GlaxoSmithKline plc’s Results
Motley Fool
Thursday, January 30, 2014 - 11:54am
tags:
GSK, earnings
Alexion Pharma Skips Out on Paying U.S. Taxes, Wall Street Says Hurrah!
TheStreet.com
Thursday, January 30, 2014 - 11:52am
tags:
Alexion, Ireland
4Q Earnings, Revs Beat by Zimmer
Yahoo/Zacks.com
Thursday, January 30, 2014 - 11:41am
tags:
Zimmer, devices, earnings
New British biotech firm to tap gene therapy for blindness
Reuters
Thursday, January 30, 2014 - 10:20am
tags:
NightstaRx, retinal distrophies, blindness
Progenics tanks after two trial deaths cast doubt on its lead program
Fierce Biotech
Thursday, January 30, 2014 - 10:18am
tags:
Progenics, PSMA ADC, prostate cancer
KaloBios calls it quits on its asthma drug after a Phase II flop
Fierce Biotech
Thursday, January 30, 2014 - 10:17am
tags:
asthma, KaloBios, KB003
The top 10 largest pharma layoffs in 2013
Fierce Pharma
Thursday, January 30, 2014 - 10:16am
tags:
layoffs
Novartis’ Fourth Quarter Earnings: 3 Key Takeaways
Motley Fool
Thursday, January 30, 2014 - 10:14am
tags:
Novartis, earnings
One-Time Gains Propel Vertex to a Profit in Q4 As Incivek Sales Plummet
Motley Fool
Thursday, January 30, 2014 - 10:12am
tags:
earnings, Vertex Pharmaceuticals
Can Pfizer Inc. Recover From Its Latest Lung Cancer Setback?
Motley Fool
Thursday, January 30, 2014 - 10:11am
tags:
Pfizer, dacomitinib, non-small cell lung cancer
Celgene's Abraxane Under Fire in NEJM Letter
TheStreet.com
Thursday, January 30, 2014 - 10:10am
tags:
New England Journal of Medicine, Abraxane, Celgene, pancreatic cancer, breast cancer, lung cancer
Oral Diabetes Medicine Shows Promise in Study of Oramed Pill
Bloomberg
Thursday, January 30, 2014 - 10:08am
tags:
diabetes, Oramed, oral insulin
Aveo Oncology to end breast cancer study due to low enrollment
Yahoo/Reuters
Thursday, January 30, 2014 - 10:07am
tags:
Aveo Oncology, Astellas, tivozanib, breast cancer, clinical trials
3 Big-Volume Biotech Stocks to Watch
TheStreet.com
Thursday, January 30, 2014 - 10:06am
tags:
biotech, Questcor, Auxilium, Prothena
Lilly Tops Earnings Estimates Despite Loss of Top Drug
Bloomberg
Thursday, January 30, 2014 - 10:04am
tags:
earnings, Eli Lilly
Roche enjoys strong profit, expects growth in 2014
Yahoo/AP
Thursday, January 30, 2014 - 10:04am
tags:
Roche, earnings
J&J Sets Drug Data Free in `YODA' Collaboration With Yale
Bloomberg/Businessweek
Thursday, January 30, 2014 - 10:03am
tags:
JNJ, clinical trial data, YODA, Yale
Novartis expects a generic of Diovan to finally arrive in April
Fierce Pharma
Wednesday, January 29, 2014 - 5:48pm
tags:
generics, Novartis, Diovan
Medivation Inc. and Astellas Up the Ante against Johnson & Johnson
Motley Fool
Wednesday, January 29, 2014 - 5:46pm
tags:
Medivation, Astellas, JNJ, Zytiga, Xtandi, prostate cancer

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.